This story has been updated to include additional comments from Illumina CEO Francis deSouza and CMO Phil Febbo.
NEW YORK – Illumina is in the process of obtaining regulatory approval for a pan-cancer genomic profiling assay in the US and Europe, which will be central to several new partnerships with pharma and genetic testing companies.
The next-generation sequencing-based clinical assay is one of several announcements Illumina CEO Francis deSouza made today at the virtual JP Morgan Healthcare Conference.